HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Elisabeth Paus Selected Research

pro-gastrin-releasing peptide (31-98)

10/2019Immunocapture sample clean-up in determination of low abundant protein biomarkers - a feasibility study of peptide capture by anti-protein antibodies.
7/2014Multiplexing determination of small cell lung cancer biomarkers and their isovariants in serum by immunocapture LC-MS/MS.
4/2014Determining ProGRP and isoforms in lung and thyroid cancer patient samples: comparing an MS method with a routine clinical immunoassay.
1/2013Digging deeper into the field of the small cell lung cancer tumor marker ProGRP: a method for differentiation of its isoforms.
8/2012Characteristics and clinical validity of two immunoassays for ProGRP.
9/2009Immuno-capture as ultimate sample cleanup in LC-MS/MS determination of the early stage biomarker ProGRP.
5/2009Absolute ProGRP quantification in a clinical relevant concentration range using LC-MS/MS and a comprehensive internal standard.
1/2009Studies on multiple forms of proGRP in serum from small cell lung cancer patients.
1/2008Progastrin-releasing peptide: stability in plasma/serum and upper reference limit.
11/2007Targeted determination of the early stage SCLC specific biomarker pro-gastrin-releasing peptide (ProGRP) at clinical concentration levels in human serum using LC-MS.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Elisabeth Paus Research Topics

Disease

13Small Cell Lung Carcinoma (Small Cell Lung Cancer)
10/2019 - 01/2007
9Neoplasms (Cancer)
06/2017 - 02/2002
7Prostatic Neoplasms (Prostate Cancer)
04/2014 - 02/2002
3Neoplasm Metastasis (Metastasis)
01/2004 - 08/2003
2Thyroid Neoplasms (Thyroid Cancer)
06/2016 - 04/2014
2Colorectal Neoplasms (Colorectal Cancer)
02/2012 - 01/2004
1Hypogonadism (Hypergonadotropic Hypogonadism)
02/2018
1Germ Cell and Embryonal Neoplasms (Germ Cell Tumor)
02/2018
1Breast Neoplasms (Breast Cancer)
06/2017
1medullary Thyroid cancer
04/2014
1Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
04/2014
1Circulating Neoplastic Cells
01/2014
1Carcinoma (Carcinomatosis)
04/2012
1Adenoma (Adenomas)
04/2012
1Neuroblastoma
08/2011
1Lung Neoplasms (Lung Cancer)
01/2007
1Hemolysis
01/2004
1Disease Progression
09/2003

Drug/Important Bio-Agent (IBA)

11pro-gastrin-releasing peptide (31-98)IBA
10/2019 - 01/2007
8Biomarkers (Surrogate Marker)IBA
10/2019 - 01/2007
8Peptides (Polypeptides)IBA
10/2019 - 11/2007
6big gastrinIBA
10/2019 - 11/2007
5Phosphopyruvate Hydratase (Enolase)IBA
07/2014 - 08/2003
5Tumor Biomarkers (Tumor Markers)IBA
01/2013 - 01/2004
3Proteins (Proteins, Gene)FDA Link
10/2019 - 01/2004
3Chorionic Gonadotropin (Human Chorionic Gonadotropin)FDA LinkGeneric
02/2018 - 09/2012
3Prostate-Specific Antigen (Semenogelase)IBA
04/2014 - 08/2003
3AndrogensIBA
01/2013 - 02/2002
2AntibodiesIBA
10/2019 - 04/2012
2Protein Isoforms (Isoforms)IBA
04/2014 - 01/2013
2Hormones (Hormone)IBA
09/2003 - 08/2003
1EpitopesIBA
10/2019
1ErbB Receptors (EGF Receptor)IBA
06/2017
1Trastuzumab (Herceptin)FDA Link
06/2017
1human ERBB2 proteinIBA
06/2017
1ThyroglobulinFDA Link
06/2016
1Formaldehyde (Formol)FDA Link
04/2012
1AS 8IBA
04/2012
1ParaffinIBA
04/2012
1Carcinoembryonic AntigenIBA
02/2012
1AntigensIBA
02/2012
1Monoclonal AntibodiesIBA
01/2007
1Hemoglobins (Hemoglobin)IBA
08/2003
1Chromogranin AIBA
08/2003
1VA 061 (VA061)IBA
02/2002
1AnthracyclinesIBA
02/2002
1liposomal doxorubicin (Doxil)FDA Link
02/2002

Therapy/Procedure

2Radiotherapy
09/2003 - 08/2003
1Castration
01/2014
1Lymph Node Excision (Lymph Node Dissection)
09/2003